Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06423170
Other study ID # SYSKY-2022-516
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2023
Est. completion date December 31, 2026

Study information

Verified date May 2024
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Zhang Rui, PhD
Phone 020-34078840
Email zhangr95@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to evaluate the efficacy and safety of Camrelizumab combined with gemcitabine and oxaliplatin (GEMOX) for unresectable gallbladder cancer. Patients with unresectable gallbladder cancer were enrolled to receive gemcitabine 1000mg/m2 D1+oxaliplatin 100mg/m2, D1+Camrelizumab 200mg, D1, in 21-day cycles for 6-8 cycles, with serum tumour markers assessed at each course and abdominal CTA performed every two courses, until tumour progression occurs.The primary indicators of this study are radical tumor resection rate; secondary indicators are disease control rate, objective response rate,progression-free survival and overall survival; safety indicators: incidence and severity of adverse events (AEs) and serious adverse events (SAEs) according to NCI-CTCAEv5.0 criteria. 37 patients are expected to be recruited for this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 37
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Patients aged 18-75 years 2. Patients with unresectable gallbladder cancer clearly diagnosed by puncture pathology or the presence of tumour cells in the bile 3. No history of chemotherapy or immunotherapy 4. ECOG score 0-1 within 1 week prior to enrollment 5. Expected survival > 3 months 6. The functional indicators of important organs meet the following requirements: (1)Neutrophils=1.5*109/L; platelets=100*109/L; hemoglobin=9g/dl; serum albumin=3g/dl; (2)Thyroid-stimulating hormone (TSH) = 2 times the upper limit of normal, and T3 and T4 are in the normal range; (3)Bilirubin = 1.5 times the upper limit of normal; ALT and AST = 3 times the upper limit of normal; (4)Serum creatinine = 1.5 times the upper limit of normal, and creatinine clearance = 60ml/min(calculated by Cockcroft-Gault formula); 7. Female subjects of childbearing potential must have had a negative serum pregnancy study within 14 days prior to the start of study treatment and be willing to use a reliable method of contraception during the study and for 60 days after the final administration of study drug 8. Male subjects whose partner is a woman of childbearing age should agree to use a reliable method of contraception for the duration of the study and for 120 days after the last dose of study drug 9. Subjects who voluntarily enter the study, sign an informed consent form, are compliant and willing to cooperate with follow-up Exclusion Criteria: 1. Past or simultaneous suffering from other malignant tumors, except for fully treated non-melanoma skin cancer, cervical carcinoma in situ, and thyroid papillary carcinoma; 2. Have used gemcitabine-based chemotherapy or have used PD-1 monoclonal antibody or PD-L1 monoclonal antibody treatment within 6 months; 3. Severe cardiopulmonary and renal dysfunction; 4. Hypertension that is difficult to control with drugs (systolic blood pressure (BP) =140 mmHg and/or diastolic blood pressure=90mmHg) (based on the average of =3 BP readings obtained by =2measurements); 5. Abnormal coagulation function (PT>14s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy; 6. After antiviral treatment, HBV DNA>2000 copies/ml, HCV RNA>1000; 7. A history of esophageal and gastric varices, significant clinically significant bleeding symptoms or a clear tendency to appear within 3 months before enrollment; 8. Active infections requiring systemic treatment; patients with active tuberculosis infection within 1 year before enrollment; a history of active tuberculosis infection more than 1 year before enrollment, and no formal anti-tuberculosis treatment or tuberculosis Still in the active period; 9. Human immunodeficiency virus (HIV, HIV1/2 antibody) positive; 10. A history of psychotropic drug abuse, alcohol or drug abuse; 11. Known to have a history of severe allergies to any monoclonal antibodies, platinum drugs, or gemcitabine; 12. Other factors judged by the investigator may affect the safety of the subjects or the compliance of the trial. Such as serious diseases (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Camrelizumab plus GEMOX
Camrelizumab:200mg,D1,intravenous infusion, the administration time is 60 (+15) minutes. GEMOX chemotherapy : oxaliplatin 100mg/m2,D1, gemcitabine1000mg/m2,D1,intravenous infusion. Carrilizumab and GEMOX chemotherapy will be intravenous infused atone day. Three weeks is a course of treatment,a total of 6-8 courses.

Locations

Country Name City State
China Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary radical tumor resection rate The proportion of patients with negative surgical resection margins in the study group 6 months
Secondary Disease Control Rate,DCR The proportion of patients whose tumours shrink or remain stable for a certain period of time and includes cases of complete remission (CR), partial remission (PR) and stable (SD). 6 months
Secondary Progress Free Survival,PFS The time between the start of treatment for disease and the observation of disease progression or the occurrence of death from any cause 6 months
Secondary Overall Survival,OS The time between the start of the diagnosis of unresectable gallbladder cancerand death from any cause 6 months
Secondary Objective response rate,ORR The proportion of patients whose tumour volume shrinks to a pre-defined value and who are able to maintain the minimum time requirement is the sum of the proportion in complete remission (CR) and partial remission (PR) 6 months
See also
  Status Clinical Trial Phase
Completed NCT00949949 - Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy Phase 1
Completed NCT01229111 - Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Phase 2
Completed NCT00238212 - S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Phase 2
Completed NCT00107536 - Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Phase 2
Completed NCT00101036 - Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Terminated NCT00478140 - Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT00356889 - Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Completed NCT00033462 - Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Phase 2
Not yet recruiting NCT05919095 - A Clinical Study of a Preoperative Translational Therapy for Unresectable Gallbladder Cancer Phase 2
Terminated NCT01282333 - Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer Phase 1
Completed NCT00397384 - Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Phase 1
Completed NCT00085410 - Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Phase 2
Completed NCT00031681 - 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Phase 1
Terminated NCT00023946 - BMS-247550 in Treating Patients With Liver or Gallbladder Cancer Phase 2
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1
Withdrawn NCT00253617 - Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Phase 3